Japanese drugmaker Takeda announced its cancer medication Ninlaro will be subject to its 340B contract pharmacy policy.
Takeda Adds Drug to 340B Contract Pharmacy Restrictions
After implementing its first contract pharmacy restrictions in January, Japanese pharmaceutical giant Takeda recently subjected another drug to conditions on [...]
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.